These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 32239385

  • 1. Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.
    Jiang S, Qin Y, Gui L, Liu P, Jiang H, Liu B, Yang J, Yang S, He X, Zhou S, Du X, Yi Y, Lin J, Shi Y.
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J, Shen X, Shi Q, Yi H, Ouyang B, Zhang Z, Gu Y, Dong L.
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S, Qin Y, Jiang H, Liu B, Shi J, Meng F, Liu P, Yang J, Yang S, He X, Zhou S, Gui L, Liu H, Lin J, Han-Zhang H, Shi Y.
    Int J Cancer; 2020 Nov 01; 147(9):2611-2620. PubMed ID: 32399964
    [Abstract] [Full Text] [Related]

  • 9. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T.
    Am J Surg Pathol; 2016 Mar 01; 40(3):324-34. PubMed ID: 26752547
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP.
    Blood; 2016 Jun 23; 127(25):3237-52. PubMed ID: 27143257
    [Abstract] [Full Text] [Related]

  • 14. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M, Perry AM, Bierman P, Loberiza F, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W, Greiner TC.
    Neuropathology; 2017 Dec 23; 37(6):509-516. PubMed ID: 28856744
    [Abstract] [Full Text] [Related]

  • 15. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH.
    Hum Pathol; 2014 Mar 23; 45(3):556-64. PubMed ID: 24444466
    [Abstract] [Full Text] [Related]

  • 16. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW, Kim Y, Lee JH, Kim YS.
    Hum Pathol; 2013 Jul 23; 44(7):1375-81. PubMed ID: 23380077
    [Abstract] [Full Text] [Related]

  • 17. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM.
    Nat Med; 2015 Aug 23; 21(8):922-6. PubMed ID: 26193343
    [Abstract] [Full Text] [Related]

  • 18. MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.
    Qin Y, Qiu T, Xie Z, Chen X, Liu P, Yang J, He X, Gui L, Zhou S, Jiang H, Zhang C, Yang S, Tang L, Shi Y.
    J Cancer Res Clin Oncol; 2023 Sep 23; 149(11):8483-8494. PubMed ID: 37093346
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB.
    Ann Hematol; 2017 Nov 23; 96(11):1867-1871. PubMed ID: 28803429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.